Background Dual antiplatelet therapy (DAPT) is the treatment of choice for patients with acute and chronic coronary syndromes as it reduces mortality and prevents recurrent thrombotic complications. The assessment of both ischaemic burden and bleeding risk is crucial in deciding which DAPT to choose and how long it should be continued. Objectives The aim of our study was to perform prospective clinical follow-up of patients receiving fixed-dose combination therapy (ASA 75 mg + clopidogrel 75 mg). Our study is a multicentric, cross-sectional, observational, cohort study. Methods A total of 1500 patients who were started on fixed-dose combination DAPT for acute or chronic coronary syndrome were included in the study. Primary endpoints were hospitalization for any reason, hospitalization for cardiovascular cause, acute myocardial infarction, stent thrombosis, target vessel revascularization and bleeding; the secondary endpoints were death for any reason or cardiovascular cause and stroke. The significance level adopted in the statistical analysis was 5%. Results Median age was 63 years; 78.5% of the patients were receiving DAPT treatment for acute coronary syndrome. The rates of hospitalization for cardiovascular reasons, acute myocardial infartion, stent thrombosis and target-vessel revascularization were 7.9%, 2.3%, 1.3% and 4.2%, respectively. While the rate of BARC type 1 bleeding was 3.3%, the rate of BARC type 5, 3, or 2 bleeding was 0.6%. The secondary endpoints which were death from any cause, cardiovascular death and stroke were 0.5%, 0.3% and 0.3%, respectively. Conclusion: Our study shows that fixed-dose combination therapy is effective and safe in appropriately selected patients with acute or chronic coronary syndromes.
Aim In heart failure (HF) patients with iron deficiency, cardiac electrical irregularity is a cause of arrhythmias. The aim of our study was to evaluate the effect of ferric carboxymaltose (FCM) treatment on T wave peak to end (Tp-e) interval and the Tp-e / QT and Tp-e / corrected QT (QTc) ratios that reflect the transmural dispersion of repolarization in HF patients with iron deficiency. Material and methods Forty HF patients with iron deficiency that were treated with FCM were included in our single center, observational study. Repolarization parameters on electrocardiograms recorded before and 12 wks after FCM treatment were compared. Additionally, these parameters were compared with ventricular repolarization parameters of 40 healthy age and gender matched individuals and with another group of 40 HF patients without iron deficiency. Results In the HF patients with iron deficiency, the Tp-e interval and the Tp-e / QT and Tp-e / QTc ratios before FCM treatment were 103.7±19.1 ms, 0.25± 0.04, 0.23±0.04, respectively. These values were higher compared to the healthy the group and HF group without iron deficiency (p<0.001). In the HF patients with iron deficiency, the Tp-e interval and the Tp-e / QT and Tp-e / QTc ratios after FCM treatment were lower compared to pre-treatment and similar to the HF patients without iron deficiency (89.4±18.6 ms, 0.22±0.04, 0.20±0.04, respectively; p<0.001). Conclusion FCM treatment of HF patients with iron deficiency corrects prolonged Tp-e interval and high Tp-e / QT and Tp-e / QTc ratios, which are risk factors for ventricular arrhythmias.
Background: Achieving target low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD) frequently requires combination lipid-lowering therapy. Single-pill combination (SPC) regimens may improve adherence compared with free-dose combinations (FDC) in real-world clinical practice. Methods: This retrospective observational study included 450 ASCVD patients with baseline LDL-C levels of 70–189 mg/dL who were followed in cardiology outpatient clinics between January 2023 and December 2024. Patients received atorvastatin–ezetimibe either as a single-pill combination (SPC, n = 392) or as a free-dose combination (FDC, n = 58). Primary endpoints were LDL-C reduction and treatment adherence (≥ 80% of prescribed doses). Secondary endpoints included LDL-C target attainment and adverse events. Non-parametric tests and chi-square/Fisher’s exact tests were used for statistical analysis. Results: At 1 month, LDL-C levels were significantly lower in the SPC group compared with the FDC group (90.6 vs. 119 mg/dL; p = 0.005), and adherence was higher (89.8% vs. 70.7%; p < 0.001). At 4 months, LDL-C levels were comparable between groups, while continuous adherence remained significantly higher in the SPC group (86% vs. 69%; p = 0.001). A higher proportion of SPC-treated patients achieved LDL-C < 100 mg/dL at 1 month (81.9% vs. 67.2%; p = 0.009). Conclusions: In this real-world ASCVD cohort, SPC therapy with atorvastatin and ezetimibe was associated with superior adherence and comparable lipid-lowering efficacy despite lower statin doses. Fixed-dose combination strategies may represent an effective approach to optimize adherence and cardiovascular risk management.
Our study aims to investigate the changes in cardiac functions, especially myocardial performance index (MPI), in patients who underwent parathyroidectomy for secondary hyperparathyroidism. Patients who underwent parathyroidectomy for secondary hyperparathyroidism between June 2010 and September 2021 were analyzed retrospectively. The patients were divided into two groups: those who underwent total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2). The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, and systolic and diastolic functions, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging. Thirty-seven patients were examined; 16 (43.2%) underwent total parathyroidectomy, and 21 (56.8%) had subtotal parathyroidectomy performed. Group 1’s mean left ventricular end-systolic diameter (LVES) decreased from 2.53 ± 0.57 to 2.35 ± 0.37 cm after parathyroidectomy. In Group 1, the postoperative value of LVES and end-systolic volume decreased significantly compared to the preoperative period (p = 0.042, p = 0.008, respectively). EF increased from 59.25 ± 0.05 to 67.81 ± 4.04. In Group 1, EF and EV postoperatively increased significantly compared to the preoperative period (p = 0.023, p = 0.021, respectively). The mean MPI decreased from 0.45 ± 0.07 to 0.39 ± 0.04 after parathyroidectomy in group 1. In group 2, it decreased from 0.46 ± 0.06 to 0.40 ± 0.04 (p < 0.001). The present study provides an improvement in myocardial functions after parathyroidectomy. While LVES, EF, ejection volume, end-systolic volume, and MPI improved in both groups, the MPI improvement was more evident in the total parathyroidectomy group. Graphical Abstract
15 April 2018 in Mersin Üniversitesi Sağlık Bilimleri Dergisi
Amaç: Kardiyovasküler hastalıklar (KVH) dünya çapında, mortalite ve morbiditenin majör nedeni olma yolunda gittikçe artan bir rol üstlenmektedir. Böylesine önemli bir sağlık sorununda, son derece yüksek maliyetle yürütülebilen tedavi çalışmalarına ek olarak primer ve sekonder korunma çalışmalarına ağırlık verilmesi gereği açıktır. Dislipidemi, koroner arter hastalığını (KAH) öngören düzeltilebilir önemli bir risk faktördür. Dünyada altı adet LDL aferez yöntemi vardır. Fakat daha önce kaskad filtrasyon yönteminin inflamatuar süreç üzerine etkilerini gösteren geniş kapsamlı bir çalışma yoktur. Yöntem: Hiperlipidemik hastalarda düşük yoğunluklu lipoprotein (LDL) aferez yöntemi olan çift filtrasyon plazmaferezi (DFPP) ve kaskad filtrasyonunun; lipid profili ve yüksek-duyarlıklı CRP (hs-CRP), üzerine etkilerinin incelenmesi amaçlı yapılmış olan çalışmamıza kardiyoloji polikliniğine başvurmuş aktif enfeksiyonu olmayan 12 hiperlipidemik hasta alındı, her hastaya 6 seans olmak üzere toplam 72 seans aferez uygulandı. Bulgular: Hiperlipidemik hastalarda aferez sonrası lipid ve hs-CRP değerleri aferez öncesine göre değerlendirildi. Aferez sonrası değerlendirilen lipid ve hs-CRP düzeyleri aferez öncesine göre istatistiksel olarak anlamlı düşük bulundu. Sonuç: Bulgularımız, maksimum diyet ve ilaç tedavisine yanıt alınamayan hiperlipidemik hastalarda lipid aferezinin; KAH tedavisinde primer ve sekonder korumada LDL kolesterol düzeyini etkin olarak düşürdüğünden mortalite ve morbiditede etkili olabileceğini desteklemektedir. Ayrıca azaltılan hs-CRP düzeylerinin aterosklerotik lezyon için olumlu katkı sağlayacağı düşünülmüştür. Hiperlipidemik hastalarda kaskad filtrasyon tekniği ile yapılan lipid aferezinin lipid düzeyi ve hs-CRP üzerindeki etkilerinin klinik sonuçları çalışmamıza göre son derece olumlu gibi görünse de, daha geniş kapsamlı, uzun süreli ve yüksek hasta sayısı ile yapılan çalışmalara ihtiyaç vardır.
Background: Contrast-induced nephropathy (CIN) is a common complication after coronary angiography (CAG), especially in patients with diabetes. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors are well known for their cardio–renal protective effects, but their impact on CIN remains unclear. This study aimed to evaluate the renal safety of SGLT-2 inhibitors in patients undergoing CAG and to examine the role of glycemic control in the risk of CIN. Methods: This retrospective study included 270 patients with type 2 diabetes who underwent elective or urgent CAG. Patients were divided into SGLT-2 users (n = 127) or non-users (n = 143). Demographic characteristics, comorbidities, laboratory data, and antidiabetic therapies were collected. CIN was defined as a ≥25% or ≥0.5 mg/dL increase in serum creatinine within 48 hours after contrast exposure. Hemoglobin A1c (HbA1c) categories were used to perform subgroup analyses. Results: The incidence of CIN was similar between SGLT-2 inhibitor users and non-users (18.1% vs. 14.7%; p = 0.447). Patients administered SGLT-2 inhibitors had higher HbA1c but lower uric acid levels. Overall, renal function decline was more evident in patients with HbA1c >6.4%; however, SGLT-2 inhibitor users showed a milder decrease in estimated glomerular filtration rate (eGFR). The frequent use of metformin and insulin may also influence CIN outcomes. Conclusions: SGLT-2 inhibitors appear to be safe during CAG and may reduce the risk of CIN in patients with poorly controlled diabetes. Larger prospective studies are required to confirm these findings.